Baker, Glen B.

Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis

Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Vohra, S., Klassen, T. P., & Baker, G. (2006) · BMJ

Circadian rhythm and melatoninSleep and related disorders

Cited by 454

The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis

Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T. P., & Vohra, S. (2005) · Journal of General Internal Medicine

Circadian rhythm and melatoninSleep and related disorders

Cited by 399

Modeling Sensitization to Stimulants in Humans: An [ 11 C]Raclopride/Positron Emission Tomography Study in Healthy Men

Boileau, I., Dagher, A., Leyton, M., Gunn, R. N., Baker, G. B., Diksic, M., & Benkelfat, C. (2006) · Archives of General Psychiatry

Neurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

Cited by 305

Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers

Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 209

Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity

Redrobe, J. P., Bourin, M., Colombel, M. C., & Baker, G. B. (1998) · Psychopharmacology

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 163

Esketamine for treatment resistant depression

Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 151

Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: a PET/[11C]raclopride study in healthy men

Leyton, M., Dagher, A., Boileau, I., Casey, K., Baker, G. B., Diksic, M., Gunn, R., Young, S. N., & Benkelfat, C. (2004) · Neuropsychopharmacology

Neurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

Cited by 95

Allopregnanolone and neuroinflammation: a focus on multiple sclerosis

Noorbakhsh, F., Baker, G. B., & Power, C. (2014) · Frontiers in Cellular Neuroscience

Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration Mechanisms

Cited by 95

An update on the role of glutamate in the pathophysiology of depression

Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 91

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects

Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry

Cannabis and Cannabinoid ResearchPsychedelics and Drug Studies

Cited by 83

Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness

Thomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 69

Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers

Asghar, S. J., Tanay, V. A. M. I., Baker, G. B., Greenshaw, A., & Silverstone, P. H. (2003) · Human Psychopharmacology: Clinical and Experimental

Bipolar Disorder and TreatmentNeurotransmitter Receptor Influence on Behavior

Cited by 64

Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action

dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 55

Amphetamine-induced dopamine release and neurocognitive function in treatment-naive adults with ADHD

Cherkasova, M. V., Faridi, N., Casey, K. F., O'Driscoll, G. A., Hechtman, L., Joober, R., Baker, G. B., Palmer, J., Dagher, A., Leyton, M., et al. (2014) · Neuropsychopharmacology

Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior

Cited by 49

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research

Schizophrenia research and treatmentTryptophan and brain disorders

Cited by 41